Goleta, Calif.– (business wire) – InOgen, Inc. Medical (Take 🙂 Weapons & Boneral.
The strategic partnership is expected to expand Iogen (Nasdaq:) Nasdaq:) China market. In addition, Yuwell, through its merger, agreed to invest approximately 27.2 million in InOgen, representing a 9.9% interest representing a 9.9% interest related to InOgen's InOgen's InOgen's InOgen's interest.
The partnership with Yuwell is a pivotal step to accelerate iOgen's iOjectory growth. By expanding our product portfolio, global presence and improving our production pipeline, we expect to be well positioned for new market opportunities, said Kevin Smith, President and Chief Executive Officer. This performance supports our commitment to deliver long-term value to our farmers and reinforces our vision to establish ionnigen as a complete patient care platform for patients worldwide. We are confident that our partnership with Yuwell will play an important role in our continued success. “
Alex Wu, chairman of Yuwell, added, InOgen is a leader in the respiratory treatment market and the strategic collaboration provides opportunities for both parties to expand the winery's reach and achieve the patient worldwide. Yuwell shares Itogen's commitment to developing and providing innovative, quality products and we believe we can make a difference in the lives of sick patients. Together, Yuwell and innin aim to define the next generation of respiratory products.
The partnership agreement will be effective immediately, while the equity purchase from itogen is expected to close in the first quarter of 2025, subject to certain customary closing conditions.
About InOgen
In Unigen, Inc. (NASSDAQ: Ingn) is a Global Medical Technology company providing global respiratory products that can be used in home settings. Iyonni supports respiratory patient care by developing, manufacturing, and marketing a class of inhalers used to deliver care to patients suffering from chronic respiratory conditions. InOgen partners with patients, home care providers, and distributors to make respiratory therapy products widely available, allowing patients the opportunity to control the impact of their disease.
For more information, please visit www.icogen.com.
Ionin has used, and is interested in continuing to use, the Gosali Investors website, http://inegen.inogen/, as a means of disclosing non-public information and complying with its FD obligations.
About Yuwell
Since its establishment in 1998, Yuwell has been at the forefront of providing medical equipment solutions to enhance patient care and improve home healthcare. Yuwell (002223.SZ) generated more than US $ 1 million dollars by 2023, and has a wide portfolio of treatments, Dinesis support products, e-mail support solutions, among other areas.
With strong promises to Kight Gise, Yuwell delivers high-quality, reliable products that empower healthcare professionals to achieve superior patient outcomes.
With state-of-the-art R & D centers and 7 main centers, Yuwewell's global presence spans 100 countries and supports more than 300,000 medical facilities. Yuwell touches the lives of patients around the world by bringing medical devices that are easy to use at home.
A forward-looking statement
These press releases are forward-looking statements within the meaning of the Privacy Act of 1995. All statements in this communication that are not historical statements, but do not include information about Itogen's business plans, market opportunities, financial trends, growth trends, and expected results of operations, are forward-looking statements. Words such as AIMS, believe, expect, plan, expect, anticipate, likely, and similar expressions are used to refer to forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties that could cause results to differ materially from the potential results of Ingen's partnership with Yuweell; Satisfaction of closing conditions under the purchase agreement for securities related to the investment; investment closing time; marketing acceptance of its products; competition; its sales, marketing and distribution power; Its strategic marketing, advertising, and research and development activities; and risks associated with international operations. For a detailed discussion of these and other risks that could impact Itogen's performance and financial performance, please refer to the images section of the 10-K report for the period December 31- IQ Leatandari ends March 31, 2024 and other filings and securities. These forward-looking statements speak only as of the date. Iogen disclaims any obligation to update these forward-looking statements unless required by law.
Check out the source image at Shirewwire.com: https://www.busewire.com/News/home/20150126900450/en/
IR@inogen.net
Source: InOgen, Inc.